APA

Kernt M., Thiele S., Neubauer A. S., Koenig S., Hirneiss C., Haritoglou C., Ulbig M. W. & Kampik A. (20121128). Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. : Retina (Philadelphia, Pa.).

Chicago

Kernt Marcus, Thiele Sarah, Neubauer Aljoscha S, Koenig Susanna, Hirneiss Christoph, Haritoglou Christos, Ulbig Michael W and Kampik Anselm. 20121128. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. : Retina (Philadelphia, Pa.).

Harvard

Kernt M., Thiele S., Neubauer A. S., Koenig S., Hirneiss C., Haritoglou C., Ulbig M. W. and Kampik A. (20121128). Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. : Retina (Philadelphia, Pa.).

MLA

Kernt Marcus, Thiele Sarah, Neubauer Aljoscha S, Koenig Susanna, Hirneiss Christoph, Haritoglou Christos, Ulbig Michael W and Kampik Anselm. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. : Retina (Philadelphia, Pa.). 20121128.